AU2014269935B2 - Human monocyte sub-population for treatment of eye diseases and disorders - Google Patents

Human monocyte sub-population for treatment of eye diseases and disorders Download PDF

Info

Publication number
AU2014269935B2
AU2014269935B2 AU2014269935A AU2014269935A AU2014269935B2 AU 2014269935 B2 AU2014269935 B2 AU 2014269935B2 AU 2014269935 A AU2014269935 A AU 2014269935A AU 2014269935 A AU2014269935 A AU 2014269935A AU 2014269935 B2 AU2014269935 B2 AU 2014269935B2
Authority
AU
Australia
Prior art keywords
cells
pbmcs
eye
disease
retina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014269935A
Other languages
English (en)
Other versions
AU2014269935A1 (en
Inventor
Inbal BENHAR BAR-ON
Michal Eisenbach-Schwartz
Ester Yoles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2014269935A1 publication Critical patent/AU2014269935A1/en
Application granted granted Critical
Publication of AU2014269935B2 publication Critical patent/AU2014269935B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2014269935A 2013-05-22 2014-05-22 Human monocyte sub-population for treatment of eye diseases and disorders Ceased AU2014269935B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361826159P 2013-05-22 2013-05-22
US61/826,159 2013-05-22
US201361915069P 2013-12-12 2013-12-12
US61/915,069 2013-12-12
PCT/IL2014/050463 WO2014188436A1 (en) 2013-05-22 2014-05-22 Human monocyte sub-population for treatment of eye diseases and disorders

Publications (2)

Publication Number Publication Date
AU2014269935A1 AU2014269935A1 (en) 2016-01-21
AU2014269935B2 true AU2014269935B2 (en) 2019-01-24

Family

ID=51933057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014269935A Ceased AU2014269935B2 (en) 2013-05-22 2014-05-22 Human monocyte sub-population for treatment of eye diseases and disorders

Country Status (11)

Country Link
US (1) US10188679B2 (https=)
EP (1) EP2999479B1 (https=)
JP (1) JP6474082B2 (https=)
KR (1) KR102257163B1 (https=)
CN (1) CN105377273A (https=)
AU (1) AU2014269935B2 (https=)
BR (1) BR112015029299A2 (https=)
CA (1) CA2913274C (https=)
IL (1) IL242694B (https=)
MX (1) MX2015016062A (https=)
WO (1) WO2014188436A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2790712B1 (en) * 2011-12-14 2016-08-31 Yeda Research and Development Co. Ltd. Human monocyte sub-population for treatment of central nervous system injury
KR20260003355A (ko) 2015-09-08 2026-01-06 후지필름 셀룰러 다이내믹스, 인코포레이티드 줄기 세포에서 유래된 망막색소상피의 macs 기반 정제
DE102017125335B4 (de) * 2017-10-27 2019-10-17 Epiontis Gmbh Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten
KR102228401B1 (ko) * 2018-07-05 2021-03-16 고려대학교 산학협력단 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델
BR112022011339A2 (pt) * 2019-12-11 2022-10-04 Myeloid Therapeutics Inc Composições de células terapêuticas e métodos para fabricação e usos das mesmas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096177A1 (en) * 2009-02-20 2010-08-26 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
AU2002353465B2 (en) 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
CA2598029A1 (en) * 2005-02-24 2006-10-05 The Scripps Research Institute Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
EP2790712B1 (en) 2011-12-14 2016-08-31 Yeda Research and Development Co. Ltd. Human monocyte sub-population for treatment of central nervous system injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096177A1 (en) * 2009-02-20 2010-08-26 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications

Also Published As

Publication number Publication date
US10188679B2 (en) 2019-01-29
EP2999479A4 (en) 2017-02-22
BR112015029299A2 (pt) 2017-07-25
WO2014188436A1 (en) 2014-11-27
CN105377273A (zh) 2016-03-02
CA2913274C (en) 2021-10-12
KR20160016874A (ko) 2016-02-15
JP6474082B2 (ja) 2019-02-27
EP2999479B1 (en) 2021-01-06
AU2014269935A1 (en) 2016-01-21
US20160166612A1 (en) 2016-06-16
MX2015016062A (es) 2016-08-03
EP2999479A1 (en) 2016-03-30
JP2016522830A (ja) 2016-08-04
CA2913274A1 (en) 2014-11-27
KR102257163B1 (ko) 2021-05-27
IL242694B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
Forrester et al. Dendritic cell physiology and function in the eye
Niederkorn Immune privilege in the anterior chamber of the eye
EP1888123B1 (en) A cellular therapy for ocular degeneration
US20200289580A1 (en) Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
AU2014269935B2 (en) Human monocyte sub-population for treatment of eye diseases and disorders
Irintchev et al. Cellular and molecular reactions in mouse muscles after myoblast implantation
JP4434729B2 (ja) 神経保護治療法のためのポリ−Ｇｌｕ，Ｔｙｒとこれで処理したＴ細胞の使用
EP2046366B1 (en) Copolymer-1 for treatment of age-related macular degeneration
US20190022198A1 (en) Individualized Immunomodulation Therapy for Neurodegenerative Disorders, CNS Injury and Age-Related Dementia
JP7738377B2 (ja) 神経炎症の調節
Adamus et al. Systemic immunotherapy delays photoreceptor cell loss and prevents vascular pathology in Royal College of Surgeons rats
JP2025118706A (ja) Ｂ細胞免疫療法
Machalińska et al. Neuroprotective and antiapoptotic activity of lineage‐negative bone marrow cells after intravitreal injection in a mouse model of acute retinal injury
Ng et al. In Vitro–Generated Autoimmune Regulatory T Cells Enhance Intravitreous Allogeneic Retinal Graft Survival
Sancho-Pelluz et al. Sialoadhesin expression in intact degenerating retinas and following transplantation
English et al. Ocular immunology
WO2021163304A1 (en) Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
Bar-On Monocyte-derived macrophages orchestrate CNS repair: Lessons from the retina and optic nerve
MachaliNska et al. Research Article Neuroprotective and Antiapoptotic Activity of Lineage-Negative Bone Marrow Cells after Intravitreal Injection in a Mouse Model of Acute Retinal Injury
HK1127858B (en) Copolymer-1 for treatment of age-related macular degeneration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired